


B cells and tertiary lymphoid structures in cancer: The knowns and the knowledge gaps



*Our goal is to increase TLS formation,
maturation, and function in cancer patients*

Tullia C. Bruno, PhD

“T cell enthusiast, B cell convert”


UPMC Hillman Cancer Center

University of Pittsburgh


Department of Immunology

June 20, 2023

tbruno@pitt.edu




How do we generate memory (virally-specific) B cells?




From *Biology* by Campbell and Reece © 2008 Pearson Education, Inc.

This occurs in secondary lymphoid organs such as lymph node, tonsil and spleen

Human tonsil





CD8 CD20 Ki67 PanCK CD45RO CD31



CD4 CD68 FoxP3 HLADR CD3e CD11c

Images obtained in Bruno lab (CODEX)

MULTIPLE immune subsets in the tumor microenvironment (TME) contribute to the immune response




Including B cells and other components of tertiary lymphoid structures (TLS)

Goal:

Harness the complete TME for improved immunotherapies

B cells and TLS correlate with improved prognosis and superior IO response

TLS are found in multiple human solid tumors




J Exp Med. 2020;218(1). doi:10.1084/jem.20200851

NEWS AND VIEWS · 15 JANUARY 2020

New predictors for immunotherapy responses sharpen our view of the tumour microenvironment



Three studies reveal that the presence in tumours of two key immune components – B cells and tertiary lymphoid structures – is associated with favourable outcomes when individuals undergo immunotherapy.



How do we maximize B cell and TLS function within the TME?



How do we think beyond the current clinical data and get to mechanism?

Resectable Melanoma



Helmink et al. *Nature* 2020 (Wargo lab)


Resectable Urothelial Carcinoma



Gao J et al., *Nat Med* 2020

Current challenges and opportunities in the B cell and TLS field


Variability of human tissue



Finding and studying TLS requires:

- State of the art spatial techniques
- Ample tissue
- Paired samples from pre and post ICI


Lack of in vivo models with TLS



Most murine models DO NOT:


- Contain TLS
- Reflect penetrance of TLS in human tissues
- Reflect TLS composition observed in patients

Lack of tools for ab recognition



Identifying what B cells recognize is:

- More complex than T cells with neoantigens
- Requires high throughput pipelines




B cells within tertiary lymphoid structures

T cell

“It takes an orchestra, not a soloist, to cure cancer”

Photograph of the Chicago Symphony Orchestra, c/o the Chicago Tribune


The B cell compartment is complex and diverse!



How do we develop an effective B cell immunotherapy?


- ✓ *Determine what B cell subpopulations are present in the TME*
- ✓ *Assess whether phenotype and function are modulated by TME*
- ✓ *Examine interactions of B cells with other cellular and non-cellular components of the TME*

There are various functions for B cells in the context of cancer



Current biological evidence points to B cells being impactful in the TME


Correlate with improved survival



- ✓ Colorectal
- ✓ Lung
- ✓ Head and Neck
- ✓ Breast
- ✓ Melanoma
- ✓ Ovarian
- ✓ Prostate
- ✓ Pancreatic

Ref: Wood et al, 2016



Produce tumor-reactive antibodies



- ✓ Of note: antibodies were derived from serum



Ref: Germain et al, 2014

Present tumor antigens to T cells



Ref: Bruno et al, CIR, 2017


What is a tertiary lymphoid structure (TLS)?



- ✓ Infiltration and segregation of CD20+ B cells and CD4+ T cells (T follicular helper lineage)
- ✓ Presence of CD21+ mature follicular dendritic cells (germinal center)
- ✓ Presence of high endothelial venules (HEV)

Combining several TLS hallmarks into a multispectral image

Infiltration and zoning of CD20⁺ B cells and CD4⁺ T cells




High endothelial venules (HEV) formation

Germinal Center (GC) formation

Nuclear
AID
CD20
CD21
CD4
Ki67
PNAAd


Presence of CD21⁺ Mature follicular dendritic cells




**Bruno
Lab**

TLS are important mediators of anti-tumor immunity



TLS composition varies



B Cell CD4⁺ T Cell CD8⁺ T Cell
T_{reg} Macrophage Tumor Cell





TLS correlate with CD8⁺ T cells



Ref: K. Ching, Goc et al, *Can Res* 2013, Helmink et al, *Nature* 2020



TLS maturity improves patient survival



Does a cellular neighborhood always have to be a TLS?

Ref: Ruffin et al, *Nat Comm* 2021


TLS are not uniform within the tumor microenvironment



***Increased TLS frequency correlates with B and T cell responses in NSCLC patients
(Bruno et al, 2017 CIR)**


What are the necessary factors to create the most functionally active intratumoral TLS?

Normal Lymphoid Tissue Tonsil



- B cells, T cells, follicular dendritic cells
- TLS initiating and maintaining factors
 - ✓ CXCL13, LTB, IL21
- Immunogenic tumor antigens
 - ✓ Virus, microbiome, immunogenic cell death
- Stromal and tumor factors
 - ✓ Mesenchymal stem cells, FRCs, fibroblasts

But what is different about the TME?



It starts with patient tissue!

Unique and robust patient cohorts
Primary tumors and metastases




Physiologically relevant
Mouse models
Mimic human TLS

State-of-the-art techniques
Spatial transcriptomics
Multispectral Imaging
scRNAseq
Cytometry



Evidence that the TME can influence TLS formation and maturation

HPV+ Tumor BOT

HPV- Tumor Larynx





AOM-DSS + *Hhep*



H. Hep specific CD4+ T follicular helper cells reside within TLS

Tumor-specific CD8+ T cells and other immune cells participate in TLS formation



Reminder: TME is not canonical!
TFH, Treg, and tumor-specific CD8+ T cells can produce CXCL13

CD8 + T cell states in human cancer: insights from single-cell analysis

[Anne M van der Leun¹](#), [Daniela S Thommen¹](#), [Ton N Schumacher²](#)

Johansson-Percival et al (Front Immunol 2021)

Lymphotoxin signaling is an important TLS inducer

Redefining the Role of Lymphotoxin Beta Receptor in the Maintenance of Lymphoid Organs and Immune Cell Homeostasis in Adulthood

Yajun Shou^{1,2}, Ekaterina Koroleva¹, Cody M. Spencer^{3†}, Sergey A. Shein¹, Anna A. Korchagina¹, Kizil A. Yusoof¹, Raksha Parthasarathy¹, Elizabeth A. Leadbetter¹, Armen N. Akopian⁴, Amanda R. Muñoz^{1‡} and Alexei V. Tumanov^{1*‡}

¹ Department of Microbiology, Immunology and Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States, ² Department of Gastroenterology, Second Xiangya Hospital of Central South University, Changsha, China, ³ Trudeau Institute, Saranac Lake, NY, United States, ⁴ Department of Endodontics, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States

Lymphotoxin β receptor signaling is required for inflammatory lymphangiogenesis in the thyroid

Glucia C. Furtado*, Tatjana Marinkovic*, Andrea P. Martin*, Alexandre Garin*, Benjamin Hoch[†], Wolfgang Hubner[‡], Benjamin K. Chen^{*‡}, Eric Genden^{*§}, Mihaela Skobe^{*¶}, and Sergio A. Lira^{*||}

*Immunology Institute and Departments of [†]Pathology, [‡]Pharmacology and Biological Chemistry, [§]Otolaryngology, and [¶]Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029-6574

Edited by Nancy Ruddle, Yale University School of Medicine, New Haven, CT, and accepted by the Editorial Board January 22, 2007 (received for review August 3, 2006)

Abnormal Development of Peripheral Lymphoid Organs in Mice Deficient in Lymphotoxin

PIETRO DE TOGNI, JOSEPH GOELLNER, NANCY H. RUDDLE, PHILIP R. STREETER, ANDREA FICK, SANJEEV MARIATHASAN, STACY C. SMITH, REBECCA CARLSON,

Laurie P. Shornick, Jena Strauss-Schoenberger, John H. Russell, Robert Karr, and David D. Chaplin

fewer

[Authors Info & Affiliations](#)


Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy

Haidong Tang¹, Mingzhao Zhu², Jian Qiao¹ and Yang-Xin Fu^{1,2}

Tertiary lymphoid structures (TLS) often develop at sites of persistent inflammation, including cancers and autoimmune diseases. In most cases, the presence of TLS correlates with active immune responses. Because of their proximity to pathological loci, TLS are an intriguing target for the manipulation of immune responses. For several years, it has become clear that lymphotoxin (LT) signalling plays critical roles in lymphoid tissue organogenesis and maintenance. In the current review, we will discuss the role of LT signalling in the development of TLS. With a focus on cancers and autoimmune diseases, we will highlight the correlations between TLS and disease progression. We will also discuss the current efforts and potential directions for manipulating TLS for immunotherapies.


Cellular & Molecular Immunology (2017) 14, 809–818; doi:10.1038/cmi.2017.13; published online 17 April 2017

Spatial transcriptomics of a lung cancer TMA reveals expression of TLS factors




■ TLS = immature or mature
■ Not TLS = Tumor no TLS
or TLS Adjacent

The stroma is complex, diverse, and essential for TLS formation



Immature and mature TLS are distinct in HGSOc

*Tissue site dictates TLS formation, contexture, maturity, and activity




Increasing TLS maturation

Genes associated with TLS maturation

LIMD2: focal adhesion, motility

TWF2: actin cytoskeletal interaction

PLEKHA2: fibronectin, cell matrix adhesion




The stroma is important!

Cancer educated mesenchymal stem cells (CA-MSCs) regulate immunity



Lan Coffman, MD PhD



Bone marrow-derived MSCs (BM-MSCs)



- Migrate to inflamed areas (TME)
- Tumor Suppressive
- Precursors of Fibroblastic Reticular Cells (FRC)
 - TNF- α and LT α 1 β

Cancer-associated MSCs (CA-MSCs)


- Reprogrammed in TME
 - Express **WT1**
- Promote tumor initiation, metastasis/chemo resistance
- A transcriptionally and epigenetically distinct population
- Immunosuppressive

Cancer reprogramming of MSCs strongly impacts TME and prognosis

A TLS biomarker is going to be essential for new clinical studies and improved IO therapies




Do we always need a germinal center for effective B cell responses?



Elsner et al 2020, *Immunity*
 Woodruff et al, 2020 *Nature Immunol*
 Jenks et al 2018, *Immunity*

Figure courtesy of Dr. Ayana Ruffin

Accumulation of EF associated memory B cells is a prominent feature of chronic infection and autoimmune disorders




Created with Biorender.com


Cellular neighborhoods can dictate memory B cell function

HPV+ BOT(TLS w/GC)

HPV- Tongue (TLS w/o GC)



TLS GC Outside TLS



Location of memory B cell subsets associates with function

Ex vivo function						
	BCR signaling	Antibody production	Isotype Switching	Differentiation	Glucose Avidity	Mitochondria integrity
SW	+++	++	+++	+++	-	+++
DN3	-	-	+++	+	+++	-/+

The proposed function of B regulatory cells




Table 1
Regulatory B cell description in the human setting

Phenotype	Activation	Action	Effect	Author
CD19 ⁺ CD24 ^{hi} CD38 ^{hi}	CD40L transfected cells	Soluble: IL-10 Contact: CD80 and CD86	Inhibition of INF- γ and TNF α CD4 ⁺ T cell secretion	Blair et al. (2010) [4]
CD27 ⁺ or CD24 ^{hi}	CpG-B and anti-Ig	Soluble: IL-10	Inhibition of effector T cell proliferation	Bouaziz et al. (2010) [3]
CD27 ⁺ CD24 ^{hi}	CpG-B and recombinant CD40L	Soluble: IL-10	Inhibition of TNF α monocyte secretion	Iwata et al. (2010) [5]



Confirmation of IL10 production is important but can be difficult to detect!


Further complexities with human Bregs

Table 1: Human regulatory B cells in health and disease: therapeutic potential

Table 1. Mechanisms of human Breg-mediated suppression

Subtype	Phenotype	Mechanism of suppression	Target of suppression	References
Immature B cells	CD24 ^{hi} CD38 ^{hi}	IL-10, PD-L1, CD80, CD86, CD1d	CD4 ⁺ T cells, CD8 ⁺ T cells, pDCs, iNKT cells	4, 18, 21, 59
B10 cells	CD24 ^{hi} CD27 ⁺	IL-10	Monocytes	13
GZMB ⁺ B cells	CD38 ⁺ CD1d ⁺ IgM ⁺ CD147 ⁺	GZMB, IL-10, IDO	CD4 ⁺ T cells	14
Br1 cells	CD25 ^{hi} CD71 ^{hi} CD73 ^{hi}	IL-10, IgG4	CD4 ⁺ T cells	19
Plasmablasts	CD27 ^{int} CD38 ^{hi}	IL-10	–	15
–	CD39 ⁺ CD73 ⁺	Adenosine	CD4 ⁺ T cells, CD8 ⁺ T cells	22
iBregs	–	TGF- β , IDO	CD4 ⁺ T cells	20
–	CD19 ⁺ TIM1 ⁺	IL-10	CD4 ⁺ T cells, CD8 ⁺ T cells	16

Cancer immunotherapies aim to reinitiate the cancer immunity cycle



How would a B cell immunotherapy fit into the current treatment model?



Targeting B cells and TLS for cancer immunotherapy

Oncolytic virus therapy
immunomodulators

Adoptive cell therapy




Cancer treatment vaccines
TLR agonists

Monoclonal antibodies
(Agonistic/blocking)



Take home messages and clinical translation

- ✓ B cells are important humoral mediators of adaptive immunity
- ✓ B cell function is dictated by cellular neighborhoods
- ✓ TLS are complex immunological hubs that are correlated with improved survival and IO response
- ✓ TLS frequency and composition is varied depending on the TME
- ✓ Spatial transcriptomics is key for revealing differences in TLS formation, maturation, and activity
- ✓ TLS initiating and TLS-maintaining factors are decreased in tumor TLS
- ✓ TLS formation and maturation is regulated by the stroma
- ✓ B-T cell crosstalk and function is dictated by TLS formation



Acknowledgements

The Bruno Lab
Ayana Ruffin
Sheryl Kunning
Ian MacFawn
Hye Mi Kim
Asia Williams
Noor Nader
Grant Magnon
Jennifer Lue
Allie Casey
Medard Kaiza
Rufiaat Rashid
Zel Zhang
Hannah Bumgarner
Alex McDonough
Caleb Lampenfeld
Mia Liu
Xiang Li
Anjali Rohatgi

Lung Cancer
Laura Stabile
 Tim Burns
 Dave Wilson
 James DeGregori (Colorado)

Ovarian Cancer
Lan Coffman
HNSCC SPORE
Robert Ferris
 Heath Skinner
 Amy Cuda
 Carly Reeder

Dario Vignali Lab
 Anthony Cillo



Team TLS
 Jen Wargo
 Tina Cascone
 Kevin McBride
 Nik Joshi
 Aaron Ring

UColorado HIMSR

Dept of Otolaryngology
 Seungwon (Steve) Kim
 Uma Duvvuri

MEL SPORE
 John Kirkwood
 Hassane Zarour
Normal tissues
 Alison Morris
 John Sembrat
 Bill Janssen (NJH-Colorado)

Cancer Bioinformatics
Riyue Bao
Raj Acharya
Brian Isett
HCC CF
Mike Meyer
Shelley Reynolds
Armando Signore



CANCER
RESEARCH
INSTITUTE®




\$\$\$\$

AACR-Johnson and Johnson
 DoD Lung Cancer Research Program
 Pfizer ESF Program
 CRI CLIP-V foundation Scholar Award
 Mark Foundation Endeavor Award
 DoD Melanoma Research Program
 U Pitt Skin SPORE
 U Pitt HNSCC SPORE
 Sy Holzer Immunotherapy Award
 UPMC Enterprises

Patients and their families!


Thank you for your attention!

Interested in B cells and TLS? Join our BC³ consortium!



Or come to our IN-PERSON Keystone—October 2023

Despite all these data, there are still key unanswered questions!



Key questions:

- By understanding the function of B cells within TLS, can we implement a novel, B cell-focused immunotherapy?
- What is the specificity of B cells in the TME?
- How do we increase tumor-specific antibody production in cancer patients?
- Does ICI modulate B cell and TLS function?
- How do B cells and TLS improve ICI?